213 related articles for article (PubMed ID: 18258654)
21. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
[TBL] [Abstract][Full Text] [Related]
22. CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives.
Janeczko M; Orzeszko A; Kazimierczuk Z; Szyszka R; Baier A
Eur J Med Chem; 2012 Jan; 47(1):345-50. PubMed ID: 22115617
[TBL] [Abstract][Full Text] [Related]
23. Characterization of ATM and DNA-PK wild-type and mutant cell lines upon DSB induction in the presence and absence of CK2 inhibitors.
Olsen BB; Fritz G; Issinger OG
Int J Oncol; 2012 Feb; 40(2):592-8. PubMed ID: 21993375
[TBL] [Abstract][Full Text] [Related]
24. Major tegument protein VP8 of bovine herpesvirus 1 is phosphorylated by viral US3 and cellular CK2 protein kinases.
Labiuk SL; Babiuk LA; van Drunen Littel-van den Hurk S
J Gen Virol; 2009 Dec; 90(Pt 12):2829-2839. PubMed ID: 19692545
[TBL] [Abstract][Full Text] [Related]
25. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
26. Toward the rational design of protein kinase casein kinase-2 inhibitors.
Sarno S; Moro S; Meggio F; Zagotto G; Dal Ben D; Ghisellini P; Battistutta R; Zanotti G; Pinna LA
Pharmacol Ther; 2002; 93(2-3):159-68. PubMed ID: 12191608
[TBL] [Abstract][Full Text] [Related]
27. Dynamic regulation of a metabolic multi-enzyme complex by protein kinase CK2.
An S; Kyoung M; Allen JJ; Shokat KM; Benkovic SJ
J Biol Chem; 2010 Apr; 285(15):11093-9. PubMed ID: 20157113
[TBL] [Abstract][Full Text] [Related]
28. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
Schneider CC; Hessenauer A; Montenarh M; Götz C
Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
[TBL] [Abstract][Full Text] [Related]
29. Halogenated imidazole derivatives block RNA polymerase II elongation along mitogen inducible genes.
Mikula M; Hanusek K; Paziewska A; Dzwonek A; Rubel T; Bomsztyk K; Ostrowski J
BMC Mol Biol; 2010 Jan; 11():4. PubMed ID: 20078881
[TBL] [Abstract][Full Text] [Related]
30. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2.
Gyenis L; Kuś A; Bretner M; Litchfield DW
J Proteomics; 2013 Apr; 81():70-9. PubMed ID: 23017496
[TBL] [Abstract][Full Text] [Related]
31. TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications.
Zień P; Abramczyk O; Domańska K; Bretner M; Szyszka R
Biochem Biophys Res Commun; 2003 Dec; 312(3):623-8. PubMed ID: 14680810
[TBL] [Abstract][Full Text] [Related]
32. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
[TBL] [Abstract][Full Text] [Related]
34. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors.
Pagano MA; Poletto G; Di Maira G; Cozza G; Ruzzene M; Sarno S; Bain J; Elliott M; Moro S; Zagotto G; Meggio F; Pinna LA
Chembiochem; 2007 Jan; 8(1):129-39. PubMed ID: 17133643
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
[TBL] [Abstract][Full Text] [Related]
36. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
Duncan JS; Litchfield DW
Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of CK2 inhibitors.
Makowska M; Łukowska-Chojnacka E; Wińska P; Kuś A; Bilińska-Chomik A; Bretner M
Mol Cell Biochem; 2011 Oct; 356(1-2):91-6. PubMed ID: 21750983
[TBL] [Abstract][Full Text] [Related]
39. Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources.
Zień P; Bretner M; Zastapiło K; Szyszka R; Shugar D
Biochem Biophys Res Commun; 2003 Jun; 306(1):129-33. PubMed ID: 12788077
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase.
Chojnacki K; Lindenblatt D; Wińska P; Wielechowska M; Toelzer C; Niefind K; Bretner M
Bioorg Chem; 2021 Jan; 106():104502. PubMed ID: 33317841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
